Clinical trial
Optimization of Adjuvant Systemic Therapy in Patients With Early HER2-Positive (HER2+) Breast Cancer or Triple Negative Breast Cancer (TNBC) That Achieved a Pathological Complete Response (pCR) After Neoadjuvant Systemic Therapy and Do Not Have Molecular Residual Disease (MRD-Negative): A Phase II Clinical Trial (The MolecularPCR Trial)
NCT07407920 is registered in ClinicalTrials.gov with M.D. Anderson Cancer Center as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Optimization of Adjuvant Systemic Therapy in Patients With Early HER2-Positive (HER2+) Breast Cancer or Triple Negative Breast Cancer (TNBC) That Achieved a Pathological Complete Response (pCR) After Neoadjuvant Systemic Therapy and Do Not Have Molecular Residual Disease (MRD-Negative): A Phase II Clinical Trial (The MolecularPCR Trial)
- Lead sponsor
- M.D. Anderson Cancer Center
- Phase
- Phase 2
- Overall status
- Recruiting
- Start date
- October 9, 2025
- Completion date
- September 30, 2028
- Enrollment
- 120 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
anatomic stage i breast cancer ajcc v8, anatomic stage ii breast cancer ajcc v8, early stage her2-positive breast carcinoma, early stage triple-negative breast carcinoma